Team:UB Indonesia/backup

From 2014.igem.org

(Difference between revisions)
 
(6 intermediate revisions not shown)
Line 389: Line 389:
These months we tried to synthesize our TALEs after clone the parts, but still there are 2 parts that not amplified yet (6A and 12E). We don’t have BsmBI restriction enzyme to Golden Gate Assembly but we found that EcoRI has the same restriction site as BsmBI. We substituted the BsmBI with EcoRI and  the parts successfully inserted into pSB1C3 (3200 bp).</p><br>
These months we tried to synthesize our TALEs after clone the parts, but still there are 2 parts that not amplified yet (6A and 12E). We don’t have BsmBI restriction enzyme to Golden Gate Assembly but we found that EcoRI has the same restriction site as BsmBI. We substituted the BsmBI with EcoRI and  the parts successfully inserted into pSB1C3 (3200 bp).</p><br>
<center><img src="https://static.igem.org/mediawiki/2014/c/c4/UB-lab_journal4.jpg" width="500px" height="200"><br>
<center><img src="https://static.igem.org/mediawiki/2014/c/c4/UB-lab_journal4.jpg" width="500px" height="200"><br>
-
Figure 4. There are two TALES we tried to synthesize, TALE 1 and TALE 2. Every TALE has triplo but only T1-2, T2-1, and T2-2 succesfully assembled.</center><br><br>
+
Figure 4. There are two TALES we tried to synthesize, TALE 1 and TALE 2. Every TALE has triplo but only T1-2, T2-1, and T2-2 succesfully assembled.</center><br>
<p align="justify">
<p align="justify">
We collected as many as possible references for the application content. Our application is android mobile based and we started to encode it. The application consist of preventing and therapy suggestion also screening method information. Special feature from our application is snap tool that can detect the kit result.
We collected as many as possible references for the application content. Our application is android mobile based and we started to encode it. The application consist of preventing and therapy suggestion also screening method information. Special feature from our application is snap tool that can detect the kit result.
Line 733: Line 733:
We upgraded the standard biobrick backbone pSB1C3 with added by promotor sequences of  p105 and GFP (E0240). This pSB1C3 has contained  chloramphenicol resistance. Our major achievements is to confirm that herbal compound can  react with promotor of HPV 16 and 18 in HeLa cells.  GFP give green colour to confirm whether herbal compound can attach and stop the HeLa cell activity transformed with p105 promotor sequence
We upgraded the standard biobrick backbone pSB1C3 with added by promotor sequences of  p105 and GFP (E0240). This pSB1C3 has contained  chloramphenicol resistance. Our major achievements is to confirm that herbal compound can  react with promotor of HPV 16 and 18 in HeLa cells.  GFP give green colour to confirm whether herbal compound can attach and stop the HeLa cell activity transformed with p105 promotor sequence
</p><br>
</p><br>
-
<center><img src="" width="" height=""></center>
+
<center><img src="https://static.igem.org/mediawiki/2014/f/f9/UB-BBa_E0240_-_P105_Map.png" width="500px" height="400"></center>
<p align="justify">
<p align="justify">
Line 739: Line 739:
Standard biobrick backbone pSB1C3 containing chloramphenicol resistance.  The backbone added  by promotor sequences of  p97 and GFP (E0240).  GFP act as a marker that give green colour to confirm  whether herbal compound can attach  and stop the HeLa cell activity transformed with p97 promotor sequence.
Standard biobrick backbone pSB1C3 containing chloramphenicol resistance.  The backbone added  by promotor sequences of  p97 and GFP (E0240).  GFP act as a marker that give green colour to confirm  whether herbal compound can attach  and stop the HeLa cell activity transformed with p97 promotor sequence.
</p><br>
</p><br>
-
<center><img src="" width="" height=""></center>
+
<center><img src="https://static.igem.org/mediawiki/2014/1/15/UB-BBa_EO240_-_p97_Map.png" width="500px" height="400"></center>
 +
<br><br>
 +
<b>Preventing and Therapy Team Safety</b>
 +
<center><table border="1">
 +
<tr><th>Part Number</th><th>DNA Source</th><th>Species Origin</th><th>Species Risk Group</th><th>Part Function</th></tr>
 +
<tr><td>Bba_K747096</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>CMV Promoter</td></tr>
 +
<tr><td>Bba_E0240</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>GFP Generator</td></tr>
 +
<tr><td>Bba_K516132</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Constitutive promoter with mRFP, RBS B0032</td></tr>
 +
<tr><td>pTALEN</td><td>From BIOSS in University of Freiburg, Germany</td><td>Xanthomonas spp.</td><td>2</td><td>Vector</td></tr>
 +
<tr><td>pTAL-TF</td><td>From BIOSS in University of Freiburg, Germany</td><td>Xanthomonas spp.</td><td>2</td><td>Vector</td></tr>
 +
<tr><td>p97 promoter</td><td>Synthesized by IDT</td><td>HPV type 16</td><td>2</td><td>Cell Line</td></tr>
 +
<tr><td>p105 promoter</td><td>Synthesized by IDT</td><td>HPV type 16</td><td>2</td><td>Cell Line</td></tr>
 +
</table>
 +
<br><br>
 +
<table border="1">
 +
<tr><th>Part Number</th><th>DNA Source</th><th>Species Origin</th><th>Species Risk Group</th><th>Part Function</th></tr>
 +
<tr><td>Bba_K747012</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747016</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747042</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747048</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747064</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747091</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747012</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747026</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747036</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747052</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747076</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747095</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Protein Domain </td></tr>
 +
<tr><td>Bba_K747101</td><td>Part registry</td><td>E. coli DH5α</td><td>1</td><td>Plasmid </td></tr>
 +
 
 +
</table>
 +
</center>
                                         </div>
                                         </div>
<h2 class="font-thin"><font color="#fff">Submitted Parts</font></h2>
<h2 class="font-thin"><font color="#fff">Submitted Parts</font></h2>
Line 772: Line 803:
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG" alt=""></a></div>
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4d/UB-Advisor.JPG" alt=""></a></div>
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg" alt=""></a></div>
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/0/03/Foto_seminar_biologi_sintetikUB.jpg" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p03-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/c/c0/UB-labwork4.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/c/c0/UB-labwork4.JPG" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p04-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/e/e0/UB-labwork1.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/e/e0/UB-labwork1.JPG" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p11-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/b/b0/UB-labwork2.JPG"><img class="thumb" src="https://static.igem.org/mediawiki/2014/b/b0/UB-labwork2.JPG" alt=""></a></div>
-
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="images/portfolio/p12-large.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/4/4b/Wiraeka.jpg" alt=""></a></div>
+
<div class="col-12 col-sm-6 col-lg-2"><a data-fancybox-group="portfolio" class="fancybox" href="https://static.igem.org/mediawiki/2014/e/e4/UB_Go_Get_GOLD.jpg"><img class="thumb" src="https://static.igem.org/mediawiki/2014/e/e4/UB_Go_Get_GOLD.jpg" alt=""></a></div>
</div><!-- /row -->
</div><!-- /row -->
</div><!-- /slide3 -->
</div><!-- /slide3 -->
Line 907: Line 938:
</div><!-- /col12 -->
</div><!-- /col12 -->
<div class="col-12 col-lg-4 col-sm-6">
<div class="col-12 col-lg-4 col-sm-6">
-
<a href="#"><p><i class="icon icon-star"></i></p></a>
+
<a href="#sponsor" class="fancybox"><p><i class="icon icon-star"></i></p></a>
 +
                                        <div id="sponsor" style="display:none;width:700px;">
 +
                                        <center><img src="https://static.igem.org/mediawiki/2014/d/d6/UB-Sponsors.jpg" width="500" height="400"></center>
 +
                                        </div>
<h2 class="font-thin"><font color="#fff">Sponsors</font></h2>
<h2 class="font-thin"><font color="#fff">Sponsors</font></h2>
</div><!-- /col12 -->
</div><!-- /col12 -->

Latest revision as of 19:18, 16 October 2014

iGEM2014 | UB INDONESIA

BRAWIJAYA UNIVERSITY , INDONESIA

This is team wiki to share our iGEM experience



iGEM UB
BRAWIJAYA UNIVERSITY
iGEM2014
PROJECT
 
Abstract ...

Background

Overview

Preventing

Screening

Therapy

NOTEBOOK
 
Description

Timeline

Lab Journal

Detail.

Protocols

Detail.

HUMAN PRACTICE
 
Teks description

Workshop

Education

Society

COLLABORATIONS
 
Description

SYNBIO FOR INDONESIA

PARTS
 
Description

Submitted Parts

Favorite Parts

ABOUT US
 
Description

Members

Sponsors

Leave us a message
 
You can find us literally anywhere,

just push a button and we’re there

in/igemub

igemub@gmail.com

Malang, Indonesia
zip code 65145

facebook/igembrawijaya

@igem_ub